edoxaban tosylate · Daiichi Sankyo Inc · NDA 206316
Savaysa
Earliest generic entry, as listed · earliest of 3 marketed strengths
28 Mar 2028
Blocked by patent: US 9149532.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9149532 | drug product · sets the listed date | 28 Mar 2028 |
| US 7365205 | drug substance | 18 Apr 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206316 · 001 · RLD | tablet, oral | EQ 15MG BASE | 28 Mar 2028 |
| 206316 · 002 · RLD | tablet, oral | EQ 30MG BASE | 28 Mar 2028 |
| 206316 · 003 · RLD | tablet, oral | EQ 60MG BASE | 28 Mar 2028 |
Expired or delisted (1)
- M-14 · 18 Oct 2026